NCT03066947 2021-01-29
SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
BriaCell Therapeutics Corporation
Phase 1/2 Completed
Clinical Trials
5 trialsNCT03552549 2019-07-24
SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT00613509 2016-04-14
Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma
Sanofi
Phase 2 Terminated
NCT00749684 2015-10-19
Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)
Merck Sharp & Dohme LLC
Completed
NCT00723710 2015-08-26
Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
Merck Sharp & Dohme LLC
Completed